Glenn Hanna, MD, and Nabil F. Saba, MD, FACP, discuss recent data on use of tipifarnib in HRAS-mutant head and neck squamous cell carcinoma.
EP. 1: The Evolving Treatment Landscape of HNSCC
A brief overview of treatment advances for HRAS-mutated head and neck squamous cell carcinoma.
EP. 2: Molecular Testing in HNSCC
Guidance for incorporating initial and repeat molecular testing in head and neck cancers into clinical practice.
EP. 3: Tipifarnib in HRAS-Mutated HNSCC
Potential implications for treating patients with HRAS-mutated head and neck cancer with tipifarnib, based on results demonstrated by the RUN-HN study.
EP. 4: Pivotal AIM-HN Clinical Trial of Tipifarnib in HNSCC
Glenn J. Hanna, MD, and Nabil F. Saba, MD, FACP, discuss the design and potential clinical implications of the AIM-HN trial of tipifarnib in head and neck cancers.
EP. 5: Future Directions in HRAS-Mutated Head and Neck Cancer
Glenn J. Hanna, MD, and Nabil F. Saba, MD, FACP, highlight potential new therapies for head and neck squamous cell carcinoma in various patient populations.
EP. 6: Managing Adverse Events With Tipifarnib
Recommendations for mitigating and managing treatment-related adverse events associated with tipifarnib.
Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC
Dr Sands on the Evolving Role of ADCs in SCLC Management
Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC
MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer